InsightRX Achieves High Performance Score in KLAS Spotlight

InsightRX has been recognized in the 2025 KLAS Emerging Company Spotlight report with a performance score of 96.1, announced in a press release. This score places InsightRX among the highest-rated vendors in clinical decision support, emphasizing its ability to enhance clinician experience, support seamless EHR integration, and deliver measurable patient outcomes.

The KLAS report highlighted InsightRX's strengths in several key areas, including integration goals, product functionality, and executive involvement. Customers reported a 100% likelihood to recommend the solution and include it in long-term plans. The platform has demonstrated significant outcomes, such as decreased medication side effects and reduced rates of acute kidney injury within six months of adoption.

Looking ahead, InsightRX is expanding its platform to cover new drug classes and therapeutic areas. The company is developing a next-generation clinical decision support tool that combines PK/PD modeling with broader clinical context inputs, aiming to optimize stewardship programs and integrate genomic data into routine care.